Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Priority Report

HERC2 Interacts with Claspin and Regulates DNA Origin Firing and Replication Fork Progression

Naoki Izawa, Wenwen Wu, Ko Sato, Hiroyuki Nishikawa, Akihiro Kato, Narikazu Boku, Fumio Itoh and Tomohiko Ohta
Naoki Izawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenwen Wu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ko Sato
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroyuki Nishikawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akihiro Kato
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Narikazu Boku
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fumio Itoh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomohiko Ohta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/0008-5472.CAN-11-0385 Published September 2011
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

DNA replication, recombination, and repair are highly interconnected processes the disruption of which must be coordinated in cancer. HERC2, a large HECT protein required for homologous recombination repair, is an E3 ubiquitin ligase that targets breast cancer suppressor BRCA1 for degradation. Here, we show that HERC2 is a component of the DNA replication fork complex that plays a critical role in DNA elongation and origin firing. In the presence of BRCA1, endogenous HERC2 interacts with Claspin, a protein essential for G2–M checkpoint activation and replication fork stability. Claspin depletion slowed S-phase progression and additional HERC2 depletion reduced the effect of Claspin depletion. In addition, HERC2 interacts with replication fork complex proteins. Depletion of HERC2 alleviated the slow replication fork progression in Claspin-deficient cells, suppressed enhanced origin firing, and led to a decrease in MCM2 phosphorylation. In a HERC2-dependent manner, treatment of cells with replication inhibitor aphidicolin enhanced MCM2 phosphorylation. Taken together, our results suggest that HERC2 regulates DNA replication progression and origin firing by facilitating MCM2 phosphorylation. These findings establish HERC2 as a critical function in DNA repair, checkpoint activation, and DNA replication. Cancer Res; 71(17); 5621–5. ©2011 AACR.

Introduction

DNA replication, recombination, and repair coordinately maintain genome stability, and their defect is a hallmark of cancer cells. The DNA replication and damage response share many critical proteins. Among them are the ATR-Chk1 pathway, which is activated in response to stalled replication forks and prevents inappropriate entry into mitosis, while it also regulates normal DNA replication by stabilizing replication forks and inhibiting excess origin firing (1, 2). Claspin is a checkpoint mediator that facilitates the phosphorylation and activation of Chk1 by ATR (3). In addition, Claspin in combination with TIPIN-TIM1-AND1 complex physically links the DNA polymerase and helicase activities, preventing fork collapse, and is required for a normal rate of fork progression (2, 4, 5).

HERC2 is a large HECT and RCC-like domain-containing protein comprising 4,834 amino acids, and has recently been implicated in homologous recombination repair of DNA double-strand breaks (DSB; ref. 6). HERC2 is recruited to sites of DSBs and facilitates assembly of the RNF8-Ubc13 complex, and is thereby essential for ubiquitin-dependent retention of repair factors (6). HERC2 is also implicated in nucleotide excision repair by ubiquitinating and degrading XPA (7, 8). In addition, we showed that HERC2 is an E3 ubiquitin ligase that targets BARD1-uncoupled BRCA1 for degradation (9). Depletion of HERC2 does not produce G2–M checkpoint failure (9) in spite of the fact that HERC2 is essential for recruiting the repair factors including BRCA1 that mediate G2–M checkpoint activation, to sites of DNA damage (6). Because depletion of HERC2 compensated for BRCA1 instability in BARD1-deficient cells and restored G2–M checkpoint function, we propose that HERC2 inhibits G2–M checkpoint function by destabilizing BRCA1. HERC2 interacts with BRCA1 and may inhibit its G2–M checkpoint function during normal S-phase or during recovery from the checkpoint. However, role of HERC2 in normal S-phase is unknown.

Because BRCA1 interacts with Claspin and acts as a second regulator of Chk1 activation (10), HERC2 may interact with Claspin and regulate DNA replication. Here, we show that HERC2 is a component of replication fork complex and regulates the fork progression and origin firing in conjunction with Claspin.

Materials and Methods

Cell culture and transfection

HCT116, Hela, HEK293T, U2OS, and either BRCA1-negative or -positive UWB1.289 cells were purchased from American Type Culture Collection and cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and 1% antibiotic-antimycotic agent. Cell lines were not further tested or authenticated. siRNA oligonucleotides targeting HERC2 (#1: 5′-GGAAAGCACUGGAUUCGUU-3′ and #2: 5′-GAAGGUGGCUGUUCACUCA-3′, sense strand), Claspin (#1: 5′-GGACGUAAUUGAUGAAGUA-3′ and #2: 5′-GGAAAUACCUGGAGGAUGA-3′, sense strand), and nontargeting control (D-001206-14) were purchased from Dharmacon. Myc-tagged N-terminus (1-2329, NT) and C-terminus (2292-4834, CT) of HERC2 fragments were subcloned in pcDNA3 by fusing smaller fragments of HERC2 as described previously (9). Transfection was carried out as previously described (11). Aphidicolin was purchased from Sigma-Aldrich.

Cell-cycle analysis

Seventy-two hours after siRNA transfection, HCT116 cells were treated with 100 ng/mL of nocodazole for 12 hours to trap cells in mitosis and to analyze a single cycle of S-phase. Bromodeoxyuridine (BrdUrd) was added for the last hour. Cells were then harvested and DNA was stained with anti-BrdUrd monocolonal antibody (mAb; Santa Cruz) and propidium iodide, and analyzed by flow cytometry as described elsewhere (12).

Immunoprecipitation, immunoblotting, and immunocytochemistry

Rabbit polyclonal antibodies to HERC2 (Bethyl Laboratories), Claspin (Bethyl Laboratories), ATRIP (Bethyl Laboratories), phospho-MCM2-S108 (Bethyl Laboratories), goat polyclonal antibodies to MCM2 (Santa Cruz) and mouse mAbs to HERC2 (BD Bioscience), MCM7 (Santa Cruz), PCNA (Neomarkers), TopBP1 (BD Bioscience), α- and β-tubulin (DMIA+BMIB, Neomarkers), Actin (Sigma), and Myc (9E10, BabCo) were purchased commercially. Immunoprecipitation and immunoblotting were done as described (11) with 0.5% NP-40–based lysis buffer in the presence or absence of benzonase nuclease (Novagen) or with RIPA buffer for whole-cell lysates (11, 13). For indirect immunocytochemistry, cells were fixed with cold methanol for 60 minutes and permeablized with cold acetone for 5 seconds. Cells were then stained as previously described (13) with the modification that blocking buffer contained 0.1% Triton X-100.

DNA fiber experiments

Forty-eight hours after siRNA transfection, cells were pulse labeled with 25 μmol/L BrdUrd for indicated time length, followed by 250 μmol/L iododeoxyuridine (IdUrd) for 20 minutes. DNA combing was carried out as described elsewhere (14, 15) with modifications. Briefly, 3,000 labeled cells spread on a glass slide were overlaid with 10 μL of buffer containing 0.5% sodium dodecyl sulfate, 200 mmol/L Tris-HCl (pH 7.4), and 50 mmol/L EDTA. After 10 minutes, the slide was tilted at 30 degrees and the resulting DNA spreads were air-dried, and fixed in 3:1 methanol/acetic acid for 5 minutes. The slides were treated with 2.5 mol/L HCl for 60 minutes, washed in PBS, and blocked in 2% bovine serum albumin in PBS for 30 minutes. The DNA fibers were then immunostained with rat anti-BrdUrd mAb and mouse anti-BrdUrd/IdUrd mAb (BD Biosciences) followed by AlexaFluor 488-conjugated chicken anti-rat IgG (Invitrogen) and AlexaFluor 555-conjugated goat anti-mouse IgG (Millipore). Fluorescent-labeled fibers were then examined with an LSM 510 confocal microscope (Carl Zeiss). The lengths of BrdUrd- (green) and IdUrd (red)-labeled patches were measured using LSM software (Carl Zeiss).

Results and Discussion

HERC2 interacts with Claspin and affects S-phase progression

To examine whether HERC2 cooperates with Claspin, we first analyzed the interaction between endogenous HERC2 and Claspin by coupled immunoprecipitation and Western blotting. HERC2 was readily detected in Claspin immunocomplexes precipitated from HCT116 or HeLa cell lysate (Fig. 1A). The interaction was diminished in BRCA1-defective UWB 1.289 cells (Fig. 1B), suggesting that BRCA1 facilitates the interaction. We next examined whether HERC2 has some role in the effect of Claspin on S-phase progression. HCT116 cells were transfected with siRNA for Claspin and/or HERC2, and the S-phase progression was analyzed with BrdUrd. The siRNA treatment successfully inhibited expression of Claspin and HERC2 (Fig. 1C; Supplementary Fig. S1). Depletion of Claspin expression increased cells in S-phase, including that in early S-phase (Fig. 1D), indicating slowed S-phase progression as previously reported (4). Importantly, additional HERC2 depletion with 2 different siRNAs both reduced the effect of Claspin depletion and decreased cells in S-phase to the level of control cells. This suggests that HERC2 suppresses S-phase progression in the absence of Claspin. Single HERC2 knockdown also slightly decreased cells in S-phase when compared with the control cells.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

HERC2 interacts with Claspin and affects S-phase progression. A and B, lysates prepared from HeLa, HCT116 (A), and BRCA1-negative and positive UWB 1.289 (B) cells were immunoprecipitated (IP) and immunoblotted (IB) with indicated antibodies. Inputs (1.5%) were also loaded. C, HCT116 cells transfected with indicated siRNA were IB with indicated antibodies. Tubulin was the loading control. D, cells from (C) were analyzed for cell cycle. The percentages of early S- (indicated with square boxes) and S-phase cells are shown in bottom. CTR, control.

HERC2 localizes at DNA replication fork

We previously showed that HERC2 and BRCA1 colocalize at S-phase nuclear foci (9). To analyze whether HERC2 localizes at DNA replication foci, exponentially proliferating HeLa cells were immunostained with anti-HERC2 antibody in combination with antibodies to proteins in the replication fork complex. Interphase cells exhibited nuclear HERC2 foci as we showed previously (9). Importantly, clear colocalization of HERC2 with nuclear PCNA foci was visualized (Fig. 2A). The colocalization was especially remarkable in cells with larger PCNA foci (light upper cell in top panels), an indication of cells in late S-phase (16). To further show the interaction between HERC2 and PCNA, HEK-293T cells were transfected with HERC2 fragments. As shown in Fig. 2B, PCNA was detected in the Myc-HERC2-CT immunocomplexes. Reciprocally, Myc-HERC2-CT was detected in PCNA immunocomplexes. The detection of the interaction was dependent on endonuclease treatment of cell lysates, suggesting that HERC2 physically interacts with PCNA complex on chromatin. HERC2 also colocalized at nuclear foci with TopBP1 and MCM7 (Fig. 2A). Together the results indicate that HERC2 is a component of the DNA replication complex.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

HERC2 localizes at DNA replication foci. A, HeLa cells were immunostained with anti-HERC2 antibody in combination with indicated antibodies. The nucleus was counterstained with DAPI. B, HEK-293T cells were transfected with Myc-HERC2-NT or CT fragment, or parental pcDNA3 vector, and lysed with or without endonuclease. Interaction between Myc-HERC2 fragments and PCNA were assessed by IP followed by IB with indicated antibodies.

HERC2 suppresses DNA replication progression in the absence of Claspin

S-phase progression is regulated by 2 main mechanisms: replication origin firing and elongation. Claspin and Chk1 stabilize replication fork and maintain elongation while they suppress excess origin firing (5, 17). Therefore the observed effect on S-phase progression in cells depleted of Claspin and/or HERC2 (Fig. 1) could result from the 2 contradictory factors. To analyze this mechanism more precisely, we used DNA combing experiments. The nascent DNAs were labeled with BrdUrd followed by IdUrd and the DNA lengths were analyzed with immunofluorescent detection. The reliability of the procedure was first verified by proportionate increase of the DNA length and labeling time length (Supplementary Fig. S2). HCT116 cells were then transfected with Claspin- or HERC2-specific siRNAs. The inhibition of HERC2 and/or Claspin expression was verified by Western blot (Fig. 3A, Supplementary Fig. S1). The lengths of the nascent DNAs in each sample were determined (Fig. 3B–D). Consistent with the previous report (4, 18), inhibition of Claspin shortened the DNA by approximately one third of that in control cells (41.4 vs. 14.0 or 14.7 kbp). Importantly, depletion of HERC2 can alleviate the slow replication fork progression in the Claspin-deficient cells (14.0 vs. 19.1 or 17.9 kbp). Interestingly, however, single HERC2 knockdown slightly shortened, rather than lengthened, the DNA lengths (41.4 vs. 35.6 or 36.5 kbp). The observed effect of HERC2 likely did not rely on its E3 activity for protein degradation, because proteasome inhibitor MG132, instead of HERC2 deletion, did not affect the nascent DNA length shortened by Claspin inhibition (Supplementary Fig. S3).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

HERC2 suppresses DNA strand elongation in the absence of Claspin. A and B, HCT116 cells transfected with the indicated siRNA were subjected to immunoblot (A) or sequentially treated with BrdUrd and IdUrd for 20 minutes each to label the nascent DNAs (B). C, representative images of labeled DNA fibers from cells with indicated siRNA measured with confocal microscopy. D, distributions of replication fork length during the entire labeling period in cells with the indicated siRNA are shown with the mean percentages (bars). Significance was analyzed by Student t test. *, P < 0.0001.

HERC2 enhances origin firing in the absence of Claspin and facilitates MCM2 phosphorylation in response to replication stress

Inhibition of Claspin leads to uncoupling of MCM helicase complex and polymerase complexes, resulting in enhanced single-strand DNA (SSD) during replication elongation (5). Therefore, the observed complement effect of HERC2 depletion on the slow replication fork progression in the Claspin-deficient cells could be explained by a direct role of HERC2 on the fork stabilization. However, HERC2 depletion in the Claspin-deficient cells did not show an obvious complementary effect on the foci formation of a SSD-binding protein RPA70 (Supplementary Fig. S4), suggesting that HERC2 is not directly involved in the fork stabilization.

We next analyzed the effect of HERC2 on origin firing. Origin firing is regulated by 2 contradictory mechanisms. Claspin and Chk1 inhibits excess origin firing while promoting elongation (17, 19). In contrast, ATR-mediated phosphorylation of MCM2 recruits Plk1, which upregulates origin firing as a compensatory mechanism for survival of replication blocks (5, 20). Supporting this mechanism, Claspin-deficient cells showed enhanced origin firing (Fig. 4A). Significantly, additional depletion of HERC2 resuppressed the origin firing to the level of that in control cells. In addition, depletion of Claspin enhanced the MCM2 phosphorylation and additional inhibition of HERC2 dramatically suppressed the MCM2 phosphorylation in the Claspin-deficient cells (Fig. 4B). To test the effect of HERC2 on replication stress in physiologic condition, we treated the cells with aphidicolin and ATRIP was immunoprecipitated. In addition to MCM2, HERC2 was coprecipitated from endonuclease-treated cell lysates (Fig. 4C; Supplementary Fig. S5). Importantly, the aphidicolin treatment increased the amount of HERC2 in the ATRIP immunocomplex (Fig. 4C). In addition, HERC2 depletion suppressed the MCM2 phosphorylation in the aphidicolin-treated cells (Fig. 4D), in similar fashion to that in the Claspin-deficient cells (Fig. 4B).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

HERC2 enhances origin firing and MCM2 phosphorylation in replication stress. A, the nascent DNAs were labeled as in Fig. 3. Representative images of the labeled DNA fibers of each origin firing or elongation pattern from control cells are shown. Arrows indicate the position of replication initiation. Bottom, quantification of origin firing in cells with the indicated siRNA. Summation of number of first label origins (red-green-red), second label origins (red only), and interspersed patterns (repeated red-green-red) are shown as percentage of all labeled tracks. Data represent the mean of triplicate experimental samples and error bars indicate SD. *, P = 0.055; **, P = 0.024 by Student t test. B, HCT116 cells were transfected with the indicated siRNA and whole-cell lysates were IB with indicated antibodies. Aphidicolin (Aph, 4 μmol/L) was added for 3 hours as a positive control for MCM2 phosphorylation. C, Hela cells untreated or treated with 4 μmol/L aphidicolin for 3 hours were IP in the presence of endonuclease, and IB with indicated antibodies. D, HCT116 cells were transfected with the indicated siRNA, untreated or treated with 1 μmol/L aphidicolin for 3 hours, and whole-cell lysates were IB with indicated antibodies. *, phosphorylated MCM2.

In summary, our results show that HERC2, an E3 ligase critical for DNA damage repair pathways, also regulates DNA replication progression and origin firing by facilitating MCM2 phosphrylation (Supplementary Fig. S6). Because HERC2 targets BRCA1 for degradation, it is possible that HERC2, Claspin, and BRCA1 cooperate on activation of Chk1 and Plk1. HERC2 in maintenance of DNA stability warrants further study into its potential roles in cancer development and therapy.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Dr. Anindya Dutta for helpful discussions and critical reading of the manuscript, and Shinko Hanaki for secretarial assistance. This study was supported by grants from the Ministry of Education, Science, Sports, Culture, and Technology of Japan.

Footnotes

  • Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

  • Received February 8, 2011.
  • Revision received June 17, 2011.
  • Accepted June 29, 2011.
  • ©2011 American Association for Cancer Research.

References

  1. 1.↵
    1. Liu Q,
    2. Guntuku S,
    3. Cui XS,
    4. Matsuoka S,
    5. Cortez D,
    6. Tamai K,
    7. et al.
    Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000;14:1448–59.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Lee J,
    2. Gold DA,
    3. Shevchenko A,
    4. Dunphy WG
    . Roles of replication fork-interacting and Chk1-activating domains from Claspin in a DNA replication checkpoint response. Mol Biol Cell 2005;16:5269–82.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Kumagai A,
    2. Kim SM,
    3. Dunphy WG
    . Claspin and the activated form of ATR-ATRIP collaborate in the activation of Chk1. J Biol Chem 2004;279:49599–608.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Petermann E,
    2. Helleday T,
    3. Caldecott KW
    . Claspin promotes normal replication fork rates in human cells. Mol Biol Cell 2008;19:2373–8.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Errico A,
    2. Costanzo V
    . Differences in the DNA replication of unicellular eukaryotes and metazoans: known unknowns. EMBO Rep 2010;11:270–8.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Bekker-Jensen S,
    2. Danielsen JR,
    3. Fugger K,
    4. Gromova I,
    5. Nerstedt A,
    6. Bartek J,
    7. et al.
    HERC2 coordinates ubiquitin-dependent assembly of DNA repair factors on damaged chromosomes. Nat Cell Biol 2009;12:80–6; sup pp. 1–12.
    OpenUrlPubMed
  7. 7.↵
    1. Kang T,
    2. Lindsey-Boltz L,
    3. Reardon J,
    4. Sancar A
    . Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase. Proc Natl Acad Sci U S A 2010;107:4890–5.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Kang TH,
    2. Reardon JT,
    3. Sancar A
    . Regulation of nucleotide excision repair activity by transcriptional and post-transcriptional control of the XPA protein. Nucleic Acids Res 2011;39:3176–87.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Wu W,
    2. Sato K,
    3. Koike A,
    4. Nishikawa H,
    5. Koizumi H,
    6. Venkitaraman AR,
    7. et al.
    HERC2 is an E3 ligase that targets BRCA1 for degradation. Cancer Res 2010;70:6384–92.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Lin SY,
    2. Li K,
    3. Stewart GS,
    4. Elledge SJ
    . Human Claspin works with BRCA1 to both positively and negatively regulate cell proliferation. Proc Natl Acad Sci U S A 2004;101:6484–9.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Nishikawa H,
    2. Ooka S,
    3. Sato K,
    4. Arima K,
    5. Okamoto J,
    6. Klevit RE,
    7. et al.
    Mass spectrometric and mutational analyses reveal Lys-6-linked polyubiquitin chains catalyzed by BRCA1-BARD1 ubiquitin ligase. J Biol Chem 2004;279:3916–24.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Yun J,
    2. Zhong Q,
    3. Kwak JY,
    4. Lee WH
    . Hypersensitivity of Brca1-deficient MEF to the DNA interstrand crosslinking agent mitomycin C is associated with defect in homologous recombination repair and aberrant S-phase arrest. Oncogene 2005;24:4009–16.
    OpenUrlPubMed
  13. 13.↵
    1. Sato K,
    2. Hayami R,
    3. Wu W,
    4. Nishikawa T,
    5. Nishikawa H,
    6. Okuda Y,
    7. et al.
    Nucleophosmin/B23 is a candidate substrate for the BRCA1-BARD1 ubiquitin ligase. J Biol Chem 2004;279:30919–22.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Jackson DA,
    2. Pombo A
    . Replicon clusters are stable units of chromosome structure: evidence that nuclear organization contributes to the efficient activation and propagation of S phase in human cells. J Cell Biol 1998;140:1285–95.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. De Haro LP,
    2. Wray J,
    3. Williamson EA,
    4. Durant ST,
    5. Corwin L,
    6. Gentry AC,
    7. et al.
    Metnase promotes restart and repair of stalled and collapsed replication forks. Nucleic Acids Res 2010;38:5681–91.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Meister P,
    2. Taddei A,
    3. Ponti A,
    4. Baldacci G,
    5. Gasser SM
    . Replication foci dynamics: replication patterns are modulated by S-phase checkpoint kinases in fission yeast. EMBO J 2007;26:1315–26.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Petermann E,
    2. Woodcock M,
    3. Helleday T
    . Chk1 promotes replication fork progression by controlling replication initiation. Proc Natl Acad Sci U S A 2010;107:16090–5.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Szyjka SJ,
    2. Viggiani CJ,
    3. Aparicio OM
    . Mrc1 is required for normal progression of replication forks throughout chromatin in S. cerevisiae. Mol Cell 2005;19:691–7.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Maya-Mendoza A,
    2. Petermann E,
    3. Gillespie DA,
    4. Caldecott KW,
    5. Jackson DA
    . Chk1 regulates the density of active replication origins during the vertebrate S phase. EMBO J 2007;26:2719–31.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Trenz K,
    2. Errico A,
    3. Costanzo V
    . Plx1 is required for chromosomal DNA replication under stressful conditions. EMBO J 2008;27:876–85.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Cancer Research: 71 (17)
September 2011
Volume 71, Issue 17
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
HERC2 Interacts with Claspin and Regulates DNA Origin Firing and Replication Fork Progression
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
HERC2 Interacts with Claspin and Regulates DNA Origin Firing and Replication Fork Progression
Naoki Izawa, Wenwen Wu, Ko Sato, Hiroyuki Nishikawa, Akihiro Kato, Narikazu Boku, Fumio Itoh and Tomohiko Ohta
Cancer Res September 1 2011 (71) (17) 5621-5625; DOI: 10.1158/0008-5472.CAN-11-0385

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
HERC2 Interacts with Claspin and Regulates DNA Origin Firing and Replication Fork Progression
Naoki Izawa, Wenwen Wu, Ko Sato, Hiroyuki Nishikawa, Akihiro Kato, Narikazu Boku, Fumio Itoh and Tomohiko Ohta
Cancer Res September 1 2011 (71) (17) 5621-5625; DOI: 10.1158/0008-5472.CAN-11-0385
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results and Discussion
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • PKCε and KRas in Lung Cancer
  • ERG Oncogene Dependency in Prostate Cancer
  • SLC43A3 as a Biomarker of 6-Thio-dG Sensitivity
Show more Priority Report
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement